The Potential Impact of FDA’s Public Disclosure Proposals

July 29, 2010
A Food and Drug Administration task force recently released 21 draft proposals that would broaden FDA’s public disclosure policies, addressing information that can be important in product liability and toxic tort litigation, including adverse events, new drug applications, clinical findings, FDA inspections, and untitled letters. This article summarizes the most significant proposals and analyzes their potential impact.